Description In vitro In vivo
ChemicalBook > CAS DataBase List > CB-839

CB-839

Description In vitro In vivo
Product Name
CB-839
CAS No.
1439399-58-2
Chemical Name
CB-839
Synonyms
CB-839;CPD1593;CS-1813;Telaglenastat;CB-839 (CB839;CB-839,TELAGLENASTAT;CB839 ;CB 839 ;CB-839;Telaglenastat (CB-839);GLS1 Inhibitor III, CB-839;Telaglenastat, 10 mM in DMSO
CBNumber
CB92718863
Molecular Formula
C26H24F3N7O3S
Formula Weight
571.57
MOL File
1439399-58-2.mol
More
Less

CB-839 Property

Melting point:
186- 189° C
Density 
1.430±0.06 g/cm3(Predicted)
storage temp. 
+2C to +8C
solubility 
Soluble in DMSO.
form 
Yellow solid
pka
8.25±0.50(Predicted)
color 
Pale yellow
Stability:
Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 2 months.
InChIKey
PRAAPINBUWJLGA-UHFFFAOYSA-N
SMILES
C1(CC(NC2=NN=C(CCCCC3=NN=C(NC(CC4=CC=CC(OC(F)(F)F)=C4)=O)C=C3)S2)=O)=NC=CC=C1
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H302Harmful if swallowed

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
5.33717
Product name
GLS1 Inhibitor III, CB-839 - CAS 1439399-58-2 - Calbiochem
Packaging
10mg
Price
$265
Updated
2025/07/31
Cayman Chemical
Product number
22038
Product name
CB-839
Purity
≥98%
Packaging
5mg
Price
$57
Updated
2024/03/01
Cayman Chemical
Product number
22038
Product name
CB-839
Purity
≥98%
Packaging
50mg
Price
$302
Updated
2024/03/01
Cayman Chemical
Product number
22038
Product name
CB-839
Purity
≥98%
Packaging
1mg
Price
$30
Updated
2021/12/16
Cayman Chemical
Product number
22038
Product name
CB-839
Purity
≥98%
Packaging
10mg
Price
$95
Updated
2024/03/01
More
Less

CB-839 Chemical Properties,Usage,Production

Description

CB-839 is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC. Phase 1.

In vitro

CB-839 exhibits time-dependent and slowly reversible kinetics. IC50 values for glutaminase inhibition by CB-839 following preincubation with rHu-GAC for-1 hour are < 50 nmol/L, at least 13-fold lower than with BPTES. CB-839 has antiproliferative activity in a triple-negative breast cancer (TNBC) cell line, HCC-1806, while no antiproliferative activity is observed in an estrogen receptor–positive cell line, T47D.

In vivo

In the mouse TNBC model, single agent CB-839 (200 mg/kg, p.o.) suppresses tumor growth by 61% relative to vehicle control. In the mouse JIMT-1 xenograft model, CB-839 alone (200 mg/kg, p.o.) results in 54% tumor growth inhibition (TGI) relative to vehicle control, combination of CB-839 (200 mg/kg, p.o.) with paclitaxel (10 mg/kg, p.o.) largely suppresses the regrowth of the tumors resulting in a TGI relative to vehicle control of 100%.

Description

CB-839 (14393999-58-2)?is a potent (IC50?= 24 nM), selective and orally bioavailable inhibitor of glutaminase (KGA and GAC).1?CB-839 displayed an antiproliferative effect in the triple-negative breast cancer cell line, HCC-1806, but no activity in the estrogen receptor-positive cell line T47D.? CB-839 was able to cause proliferation arrest and apoptosis in acute myeloid leukemia cells without causing cytotoxicity against normal human CD34(+) progenitors.2? Aspartate-glutamate carrier 1 (AGC1) inhibition can synergize with CB-839 to limit tumor growth.3

Uses

CB-839 performs an antileukemic activity. It Inhibits GLS1 genes and reduces oxidative phosphorylation leading to leukamic cell proliferation arrest and apoptosis.

Synthesis

13115-43-0

1439399-45-7

1439399-58-2

In a 250 mL three-necked round-bottomed flask, N-[6-[4-(5-amino-1,3,4-thiadiazol-2-yl)butyl]-3-pyridazinyl]-3-(trifluoromethoxy)benzeneacetamide (5.5 g, 12.3 mmol, 1.0 eq.) was dissolved in N,N-dimethylacetamide (44 mL, 8.0 v/v). Pyridine-2-acetic acid (2.56 g, 14.8 mmol, 1.2 equiv) was added. Propylphosphonic anhydride (50% ethyl acetate solution, 11.0 g, 17.3 mmol, 1.41 eq.) was added dropwise through the addition funnel at a rate of 5 mL/min. During the dropwise addition, the internal temperature of the reaction solution was increased from 20.1°C to 26.1°C. The reaction was typically completed after 4 h (monitored by LC/MS). Upon completion of the reaction, the reaction solution was cooled to 0°C and diluted with methyl ethyl ketone (50 mL). Water (50 mL) was added and the pH was adjusted to 6 with 2.5 N aqueous sodium hydroxide (28 mL). a yellow precipitate was collected by diafiltration and washed with isopropanol and water (1:1, 50 mL). The solid was transferred to a 100 mL round bottom flask and slurried in isopropanol and water (9:1, 50 mL). The slurry was heated to 65.1 °C and maintained for 8 h, followed by cooling to room temperature over 16 h. The slurry was then removed from the flask. An off-white precipitate was collected by filtration and washed with isopropanol (10 mL). The product was dried under high vacuum to constant weight to afford 2-(pyridin-2-yl)-N-(5-(5-(4-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridazin-3-yl)butyl)-1,3,4-thiadiazol-2-yl)acetamide (CB-839) in a yield of 5.27 g (76%).1H NMR (300 MHz, DMSO-d6) δ 12.67 (s, 1H), 11.32 (s, 1H), 8.53-8.49 (m, 1H), 8.22-8.19 (d, J=9.12Hz, 1H), 7.78-7.76 (t, 1H), 7.58-7.26 (m, 7H), 4.01 (s, 2H), 3.87 (s, 2H), 3.01 (bs, 2H) , 2.90 (bs, 2H), 1.73 (bs, 4H).The XRD pattern (form B) of the free base of CB-839 is shown in Fig. 2, with characteristic peaks located at 2θ values of 3.64; 7.32; 7.92; 8.53; 9.30; 9.38; 11.02; 11.98; 14.70; 15.54; 15.87; 16.50 16.59; 18.06; 18.39; 19.10; 20.06; 20.12; 20.61; 21.37; 21.89; 22.41; 22.74; 23.72; 24.10; 24.65; 25.14; 25.78; 26.49; 27.32; 27.55; 28.26; 29.88. 31.20; 31.80; 31.52; 32.80; 34.30; 35.20; 36.41; 38.53; 40.08; 40.94; and 43.86.

in vivo

Telaglenastat (CB-839) (200 mg/kg; p.o.; twice daily for 28 days) has antitumor activity in xenograft models of TNBC[1].

Animal Model:Female nu/nu mice with age 4–6 weeks (TNBC patient-derived xenograft model)[1]
Dosage:200 mg/kg
Administration:Oral administration; twice daily for 28 days
Result:Suppressed tumor growth by 61% relative to vehicle control at the end of study.

storage

Store at -20°C

References

[1] MATT I GROSS. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.[J]. Molecular Cancer Therapeutics, 2014, 13 4: 890-901. DOI:10.1158/1535-7163.mct-13-0870
[2] NATHALIE JACQUE. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.[J]. Blood, 2015, 126 11: 1346-1356. DOI:10.1182/blood-2015-01-621870
[3] H FURKAN ALKAN. Cytosolic Aspartate Availability Determines Cell Survival When Glutamine Is Limiting.[J]. Cell metabolism, 2018, 28 5: 706-720.e6. DOI:10.1016/j.cmet.2018.07.021

CB-839 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

CB-839 Suppliers

Hangzhou ChangCun Biotechnology Co., Ltd.
Tel
0571-; 13567100326
Fax
QQ158848739
Email
158848739@qq.com
Country
China
ProdList
108
Advantage
50
DKMbiochem.Co. Ltd
Tel
15901859516
Fax
15901859516
Email
sales@DKMbiochem.com
Country
China
ProdList
344
Advantage
58
Changzhou PBpharmaceutical R&D Co.,Ltd
Tel
086-0519-83990708 18915800124
Fax
0519-83990708
Email
info@pbpharm.com
Country
China
ProdList
487
Advantage
55
ShangHai Caerulum Pharma Discovery Co., Ltd.
Tel
18149758185
Email
sales-cpd@caerulumpharma.com
Country
China
ProdList
3506
Advantage
58
Zibo Biopolar Rongchuang Pharmaceutical Co. Ltd.
Tel
0533-6092686 13371592196
Email
ddliu@bio-polar.cn
Country
China
ProdList
2229
Advantage
58
Shanghai Boyle Chemical Co., Ltd.
Tel
Fax
86-21-57758967
Email
sales@boylechem.com
Country
China
ProdList
2922
Advantage
55
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Fax
021-58180499
Email
sales@BioChemBest.com
Country
China
ProdList
6003
Advantage
61
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
sales@meilune.com
Country
China
ProdList
4747
Advantage
58
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Fax
(86) 21-58955996
Email
info@chemexpress.com
Country
China
ProdList
7552
Advantage
61
AdooQ BioScience, LLC
Tel
+1 (866) 930-6790
Fax
+1 (866) 333-9607
Email
info@adooq.com
Country
United States
ProdList
2782
Advantage
58
More
Less

View Lastest Price from CB-839 manufacturers

Henan Aochuang Chemical Co.,Ltd.
Product
CB-839 1439399-58-2
Price
US $0.00-0.00/KG
Min. Order
1KG
Purity
98%
Supply Ability
1Ton
Release date
2022-10-13

1439399-58-2, CB-839Related Search:


  • 2-(pyridin-2-yl)-N-(5-(4-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridazin-3-yl)butyl)-1,3,4-thiadiazol-2-yl)acetamide CB-839
  • 2-(pyridin-2-yl)-N-(5-(4-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridazin-3-yl)butyl)-1,3,4-thiadiazol-2-yl)acetamide
  • CPD1593
  • CB-839
  • N-[5-[4-[6-[[2-[3-(trifluoromethoxy)phenyl]acetyl]amino]-3-pyridazinyl]butyl]-1,3,4-thiadiazol-2-yl]-2-pyridineacetamide
  • CB839 ;CB 839 ;CB-839
  • GLS1 Inhibitor III, CB-839 - CAS 1439399-58-2 - Calbiochem
  • CB-839,TELAGLENASTAT
  • Telaglenastat
  • CS-1813
  • 2-Pyridineacetamide, N-[5-[4-[6-[[2-[3-(trifluoromethoxy)phenyl]acetyl]amino]-3-pyridazinyl]butyl]-1,3,4-thiadiazol-2-yl]-
  • Telaglenastat (CB-839)
  • Glutaminase,antiproliferative,HCC-1806,TNBC,Telaglenastat,breast,Inhibitor,Autophagy,splice,cell,PDAC,variants,selective,cancer,triple-negative,inhibit
  • Telaglenastat, 10 mM in DMSO
  • GLS1 Inhibitor III, CB-839
  • CB-839 (CB839
  • Telaglenastat (CB-839) ,S7655
  • 1439399-58-2
  • C26H24F3N7O3S